Table 2.
Microtube-stabilizing agents.
| Chemical lead | Properties and effects | Clinical trial/status | References |
|---|---|---|---|
| Epothilones | Elevated water solubility, activity versus MDR cell lines, and chemical malleability. | Phase II/III clinical trials in taxane-sensitive solid tumors (breast, lung, and prostate). | [195, 196] |
|
| |||
| Ixabepilone | Epothilone B analog, superior metabolic stability, and activity versus MDR cell lines. | Approved in 2007 for metastatic breast cancer; several ongoing trials in solid tumors. | [194, 197] |
|
| |||
| Laulimalide | Activity versus MDR cell lines and angiogenic activity, synergistic with docetaxel. | Preclinical phase. | [199, 201] |
|
| |||
| Dictyostatin | Activity against MDR cell lines, synergistic with taxol. | Preclinical phase. | [205, 206] |